The advent of AAV9 expands applications for brain and spinal cord gene delivery

Expert Opinion on Biological Therapy

Volumn 12, Issue 6, 2012, Pages 757-766

  Dayton, Robert D ^a   Wang, David B ^b   Klein, Ronald L ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Adeno associated virus; Amyotrophic lateral sclerosis; Frontotemporal lobar degeneration; Gene therapy; Gene transfer; Lysosomal storage disease; Microtubule associated protein tau; Spinal cord; Spinal muscular atrophy; TDP 43

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; NEUTRALIZING ANTIBODY; SOMATOMEDIN C; TAR DNA BINDING PROTEIN; TAU PROTEIN; VASCULOTROPIN;

ADENO ASSOCIATED VIRUS; ADENO ASSOCIATED VIRUS 9; AMYOTROPHIC LATERAL SCLEROSIS; BRAIN; DEGENERATIVE DISEASE; FRONTOTEMPORAL DEMENTIA; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; GENE TRANSFER; LYSOSOME STORAGE DISEASE; MUCOPOLYSACCHARIDOSIS; MULTIPLE SULFATASE DEFICIENCY; NERVE CELL; NONHUMAN; PARKINSON DISEASE; REVIEW; SEROTYPE; SPINAL CORD; SPINAL MUSCULAR ATROPHY; SUBSTANTIA NIGRA; VIRUS CAPSID;

ANIMALS; BRAIN; DEPENDOVIRUS; GENE EXPRESSION REGULATION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, INTRAVENTRICULAR; INJECTIONS, SPINAL; NEURONS; SPINAL CORD;

ADENO-ASSOCIATED VIRUS; MUS;

EID: 84861326894     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.681463     Document Type: Review

References (74)

1. Klein RL, Wang DB, King MA. Versatile somatic gene transfer for modeling neurodegenerative diseases. Neurotox Res 2009;16:329-342
2. McCown TJ. Adeno-associated virus (AAV) vectors in the CNS. Curr Gene Ther 2011;11:181-188
3. Lentz TB, Gray SJ, Samulski RJ. Viral vectors for gene delivery to the central nervous system. Neurobiol Dis 2011; [Epub ahead of print]
4. Berns KI, Linden RM. The cryptic life style of adeno-associated virus. Bioessays 1995;17:237-245
5. Kaplitt MG, Leone P, Samulski RJ, et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet 1994;8:148-154
6. McCown TJ, Xiao X, Li J, et al. Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Res 1996;713:99-107
7. Gao G, Vandenberghe LH, Alvira MR, et al. Clades of Adeno-associated viruses are widely disseminated in human tissues. J Virol 2004;78:6381-6388
8. Burger C, Gorbatyuk OS, Velardo MJ, et al. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther 2004;10:302-317
9. Klein RL, Dayton RD, Leidenheimer NL, et al. Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent protein. Mol Ther 2006;13:517-527
10. Cearley CN, Wolfe JH. Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol Ther 2006;13:528-537
11. Klein RL, Dayton RD, Tatom JB, et al. AAV8, 9, Rh10, Rh43 vector gene transfer in the rat brain: Effects of serotype, promoter and purification method. Mol Ther 2008;16:89-96
12. Klein RL, Dayton RD, Tatom JB, et al. Tau expression levels from various adeno-associated virus vector serotypes produce graded neurodegenerative disease states. Eur J Neurosci 2008;27:1615-1625
13. Foust KD, Nurre E, Montgomery CL, et al. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 2009;27:59-65
14. Duque S, Joussemet B, Riviere C, et al. Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther 2009;17:1187-1196
15. Foust KD, Poirier A, Pacak CA, et al. Neonatal intraperitoneal or intravenous injections of recombinant adeno-associated virus type 8 transduce dorsal root ganglia and lower motor neurons. Hum Genet Ther 2008;19:61-70
16. Saunders NR, Joakim Ek C, Dziegielewska KM. The neonatal blood-brain barrier is functionally effective, and immaturity does not explain differential targeting of AAV9. Nat Biotechnol 2009;27:804-805
17. Koerber JT, Klimczak R, Jang JH, et al. Molecular evolution of adeno-associated virus for enhanced glial gene delivery. Mol Ther 2009;17(12):2088-2095
18. Wang DB, Dayton RD, Henning PP, et al. Expansive gene transfer in the rat CNS rapidly produces amyotrophic lateral sclerosis relevant sequelae when TDP-43 is overexpressed. Mol Ther 2010;18:2064-2074
19. McCarty DM, Monahan PE, Samulski RJ. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther 2001;8:1248-1254
20. Miyake N, Miyake K, Yamamoto M, et al. Global gene transfer into the CNS across the BBB after neonatal systemic delivery of single-stranded AAV vectors. Brain Res 2011;1389:19-26
21. Rahim AA, Wong AMS, Hoefer K, et al. Intravenous administration of AAV2/9 to the fetal and neonatal mouse leads to differential targeting of CNS cell types and extensive transduction of the nervous system. FASEB J 2011;25:3505-3518
22. Zhang H, Yang B, Mu X, et al. Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol Ther 2011;19:1440-1448
23. Foust KD, Wang X, McGovern VL, et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol 2010;28:271-274
24. Bevan AK, Duque S, Foust KD, et al. Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Mol Ther 2011;19:1971-1980
25. Inagaki K, Fuess S, Storm TA, et al. Robust systemic transduction with AAV9 vectors in mice: Efficient global cardiac gene transfer superior to that of AAV8. Mol Ther 2006;14:45-53
26. Zincarelli C, Soltys S, Rengo G, Rabinowitz JE. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 2008;16:1073-1080
27. Gray SJ, Matagne V, Bachaboina L, et al. Preclinical differences of intravascular AAV9 delivery to neurons and glia: A comparative study of adult mice and nonhuman primates. Mol Ther 2011;19:1058-1069
28. Samaranch L, Salegio EA, San Sebastian W, et al. AAV9 transduction in the central nervous system of non-human primates. Hum Gene Ther 2011; [Epub ahead of print]
29. Sanftner LM, Suzuki BM, Doroudchi MM, et al. Striatal delivery of rAAV-hAADC to rats with preexisting immunity to AAV. Mol Ther 2004;9:403-409
30. Peden CS, Burger C, Muzyczka N, Mandel RJ. Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain. J Virol 2004;78:6344-6359
31. Snyder BR, Gray SJ, Quach ET, et al. Comparison of adeno-associated viral vector serotypes for spinal cord and motor neuron gene delivery. Hum Genet Ther 2011;22:1129-1135
32. Federici T, Taub JS, Baum GR, et al. Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs. Gene Ther 2011; [Epub ahead of print]
33. Mattar CN, Waddington SN, Biswas A, et al. Systemic delivery of scAAV9 in fetal macaques facilitates neuronal transduction of the central and peripheral nervous systems. Gene Ther 2012; [Epub ahead of print]
34. Xu R, Janson CG, Mastakov M, et al. Quantitative comparison of expression with adeno-associated virus (AAV-2) brain-specific gene cassettes. Gene Ther 2001;8:1323-1332
35. Gray SJ, Foti SB, Schwartz JW, et al. Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors. Hum Genet Ther 2011;22:1143-1153
36. Huang C, Tong J, Bi F, et al. Mutant TDP-43 in motor neurons promotes the onset and progression of ALS in rats. J Clin Invest 2012;122:107-118
37. Xie J, Xie Q, Zhang H, et al. MicroRNA-regulated, systemically delivered rAAV9: A step closer to CNS-restricted transgene expression. Mol Ther 2011;19:526-535
38. McCarty DM, DiRosario J, Gulaid K, et al. Mannitol-facilitated CNS entry of rAAV2 vector significantly delayed the neurological disease progression in MPS IIIB mice. Gene Ther 2009;16:1340-1352
39. Fu H, Dirosario J, Killedar S, et al. Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery. Mol Ther 2011;19:1025-1033
40. 40, Gray SJ, Blake BL, Criswell HE, et al. Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised bloodbrain barrier (BBB). Mol Ther 2010;18:570-578
41. Passini MA, Bu J, Roskelley EM, et al. CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy. J Clin Invest 2010;120:1253-1264
42. Boillee S, Vande Velde C, Cleveland DW. ALS: A disease of motor neurons and their nonneuronal neighbors. Neuron 2006;52(1):39-59; Review
43. Fecto F, Siddique T. Making connections: Pathology and genetics link amyotrophic lateral sclerosis with frontotemporal lobe dementia. J Mol Neurosci 2011;45:663-675
44. Wang DB, Gitcho MA, Kraemer BC, et al. Genetic strategies to study TDP-43 in rodents and to develop preclinical therapeutics for amyotrophic lateral sclerosis. Eur J Neurosci 2011;34:1179-1188
45. Nizzardo M, Simone C, Falcone M, et al. Research advances in gene therapy approaches for the treatment of amyotrophic lateral sclerosis. Cell Mol Life Sci 2011; [Epub ahead of print]
46. Federici T, Boulis NM. Gene therapy for amyotrophic lateral sclerosis. Neurobiol Dis 2011 Aug 25; [Epub ahead of print]
47. Fechner H, Sipo I, Westermann D, et al. Cardiac-targeted RNA interference mediated by an AAV9 vector improves cardiac function in coxsackievirus B3 cardiomyopathy. J Mol Med (Berl) 2008;86:987-997
48. Kornegay JN, Li J, Bogan JR, et al. Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs. Mol Ther 2010;18:1501-1508
49. Xue YQ, Ma BF, Zhao LR, et al. AAV9-mediated erythropoietin gene delivery into the brain protects nigral dopaminergic neurons in a rat model of Parkinson's disease. Gene Ther 2010;17:83-94
50. Cearley CN, Wolfe JH. A single injection of an adeno-associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neurogenetic disease. J Neurosci 2007;27:9928-9940
51. Spampanato C, De Leonibus E, Dama P, et al. Efficacy of a combined intracerebral and systemic gene delivery approach for the treatment of a severe lysosomal storage disorder. Mol Ther 2011;19:860-869
52. Bevan AK, Hutchinson KR, Foust KD, et al. Early heart failure in the SMNDelta7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN delivery. Hum Mol Genet 2010;19:3895-3905
53. Valori CF, Ning K, Wyles M, et al. Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Sci Transl Med 2010;2:35ra42
54. Dominguez E, Marais T, Chatauret N, et al. Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum Mol Genet 2011;20:681-693
55. Glascock JJ, Shababi M, Wetz MJ, et al. Direct central nervous system delivery provides enhanced protection following vector mediated gene replacement in a severe model of spinal muscular atrophy. Biochem Biophys Res Commun 2012;417:376-381
56. Harvey BK, Richie CT, Hoffer BJ, et al. Transgenic animal models of neurodegeneration based on human genetic studies. J Neural Transm 2011;118:27-45
57. Dodge JC, Haidet AM, Yang W, et al. Delivery of AAV-IGF-1 to the CNS extends survival in ALS mice through modification of aberrant glial cell activity. Mol Ther 2008;16:1056-1064
58. Dodge JC, Treleaven CM, Fidler JA, et al. AAV4-mediated expression of IGF-1 and VEGF within cellular components of the ventricular system improves survival outcome in familial ALS mice. Mol Ther 2010;18:2075-2084
59. Miller TM, Kaspar BK, Kops GJ, et al. Virus-delivered small RNA silencing sustains strength in amyotrophic lateral sclerosis. Ann Neurol 2005;57:773-776
60. Decressac M, Mattsson B, Bjorklund A. Comparison of the behavioural and histological characteristics of the 6-OHDA and alpha-synuclein rat models of Parkinson's disease. Exp Neurol 2012; [Epub ahead of print]
61. Kumar-Singh S, Van Broeckhoven C. Frontotemporal lobar degeneration: Current concepts in the light of recent advances. Brain Pathol 2007;17:104-114
62. Geser F, Lee VM, Trojanowski JQ. Amyotrophic lateral sclerosis and frontotemporal lobar degeneration: A spectrum of TDP-43 proteinopathies. Neuropathology 2010;30:103-112
63. Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006;314:130-133
64. Klein RL, Dayton RD, Diaczynsky CG, Wang DB. Pronounced microgliosis and neurodegeneration in aged rats after tau gene transfer. Neurobiol Aging 2010;31:2091-2102
65. Tatom JB, Wang DB, Dayton RD, et al. Mimicking aspects of frontotemporal lobar degeneration and Lou Gehrig's disease in rats via TDP-43 overexpression. Mol Ther 2009;17:607-613
66. Haberman RP, McCown TJ, Samulski RJ. Inducible long-term gene expression in brain with adeno-associated virus gene transfer. Gene Ther 1998;5:1604-1611
67. Dayton RD, Wang DB, Cain CD, et al. Frontotemporal lobar degeneration-related proteins induce only subtle memory-related deficits when bilaterally overexpressed in the dorsal hippocampus. Exp Neurol 2012;233:807-814
68. Uchida A, Sasaguri H, Kimura N, et al. Non-human primate model of amyotrophic lateral sclerosis with cytoplasmic mislocalization of TDP-43. Brain 2012; Epub ahead of print
69. Wang C, Wang CM, Clark KR, Sferra TJ. Recombinant AAV serotype 1 transduction efficiency and tropism in the murine brain. Gene Ther 2003;10:1528-1534
70. Sondhi D, Hackett NR, Peterson DA, et al. Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector. Mol Ther 2007;15:481-491
71. White E, Bienemann A, Sena-Esteves M, et al. Evaluation and optimization of the administration of recombinant adenoassociated viral vectors (serotypes 2/1, 2/2, 2/rh8, 2/9, and 2/rh10) by convection-enhanced delivery to the striatum. Hum Gene Ther 2011;22:237-251
72. Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges. Nat Rev Genet 2011;12:341-355
73. Wilson JM. It's time for gene therapy to get disruptive! Hum Gene Ther 2012;23:1-3
74. Lin Y, Roman K, Foust KD, et al. Glutamate transporter GLT-1 upregulation attenuates visceral nociception and hyperalgesia via spinal mechanisms not related to anti-inflammatory or probiotic effects. Pain Res Treat 2011; [Epub ahead of print]